Fortrea Holdings Inc. (FTRE)
FTRE or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Fortrea Holdings Inc. (FTRE) Beats Q1 Earnings Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.18 per share a year ago.
FTRE vs. PRTA: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
FTRE or ACAD: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Fortrea Holdings Inc. (FTRE) Shows Fast-paced Momentum But Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortrea Holdings Inc. (FTRE) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
FTRE vs. ACAD: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Fortrea Holdings Inc. (FTRE) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last?
Fortrea Holdings Inc. (FTRE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Fortrea Holdings Inc. (FTRE) Q3 2025 Earnings Call Transcript
Fortrea Holdings Inc. ( FTRE ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tracy Krumme - Senior VP of Investor Relations Anshul Thakral - CEO & Director Jill McConnell - Chief Financial Officer Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division David Windley - Jefferies LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jenny Cao - Truist Securities, Inc., Research Division Alan Chen Presentation Operator Good day, and thank you for standing by.
Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.23 per share a year ago.
